Delivery Order SPE2DR25D3109-SPE2DR26FT2MK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,740.56 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 9, 2026, with a completion date of January 12, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award is issued under AmerisourceBergen's parent company Cencora, Inc.'s Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at...
- The Defense Logistics Agency awarded a delivery order valued at $108,228.44 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This firm fixed-price, non-set-aside contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $13,116.80 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 6, 2026, with an ultimate completion date of January 7, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $19,675.26 delivery order to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of RINVOQ ER 15mg tablets (30-count bottles). This is a firm fixed-price, non-set-aside contract with a completion date of January 14, 2026, and performance location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up...
- The Defense Logistics Agency awarded a delivery order valued at $6,762.36 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) on January 13, 2026, with an ultimate completion date of January 14, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a single task order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $10,807.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 8, 2026, with an ultimate completion date of January 9, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) valued at $3,111.66 under a firm fixed-price contract. The award, announced on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive, non-set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $32,674.07 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This firm fixed-price contract, which was not set aside for any specific business classification, represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX). The parent company, Cencora, Inc. (doing...
- The Defense Logistics Agency awarded a delivery order valued at $26,892.34 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $3,279.20 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on January 13, 2026, with a completion date of January 14, 2026. This non-set-aside, competitively awarded contract was issued as a firm fixed-price delivery order and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major...
- SPE2DR25D3109Indefinite Delivery Contract
- SPE2DR25D3109-SPE2DR26FT2MKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,724.33 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This is a firm fixed-price, non-set-aside contract performed at the contractor's headquarters in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor specializing in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to military and veteran healthcare systems. The company has demonstrated capability to meet federal procurement requirements through competitive awards and maintains an extensive portfolio of medical product deliveries with DLA and other federal agencies. RINVOQ is a Janus kinase inhibitor indicated for rheumatoid arthritis and other inflammatory conditions, supporting the company's role in delivering specialty medications essential to military treatment facilities and federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 1/11/26 |